Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
Chr del(17p)
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related tests:
Vysis CLL FISH Probe Kit (2)
Vysis CLL FISH Probe Kit (2)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + ibrutinib
Sensitive: A1 - Approval
venetoclax + ibrutinib
Sensitive
:
A1
venetoclax + ibrutinib
Sensitive: A1 - Approval
venetoclax + ibrutinib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
rituximab + idelalisib
Sensitive: A1 - Approval
rituximab + idelalisib
Sensitive
:
A1
rituximab + idelalisib
Sensitive: A1 - Approval
rituximab + idelalisib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
acalabrutinib
Sensitive: A1 - Approval
acalabrutinib
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
idelalisib + ofatumumab
Sensitive: A1 - Approval
idelalisib + ofatumumab
Sensitive
:
A1
idelalisib + ofatumumab
Sensitive: A1 - Approval
idelalisib + ofatumumab
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
rituximab + idelalisib
Sensitive: A2 - Guideline
rituximab + idelalisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
venetoclax + rituximab
Sensitive: A2 - Guideline
venetoclax + rituximab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive: A2 - Guideline
rituximab + alemtuzumab
Sensitive
:
A2
rituximab + alemtuzumab
Sensitive: A2 - Guideline
rituximab + alemtuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
venetoclax + obinutuzumab
Sensitive
:
A2
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
venetoclax + obinutuzumab
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: A2 - Guideline
acalabrutinib
Sensitive
:
A2
acalabrutinib
Sensitive: A2 - Guideline
acalabrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
obinutuzumab + acalabrutinib
Sensitive
:
A2
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
obinutuzumab + acalabrutinib
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
rituximab + lenalidomide
Sensitive: A2 - Guideline
rituximab + lenalidomide
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login